{"prompt": "['Protocol Identifying Number: PS-001', 'Protocol Version: 1.0', 'Protocol Date: 10 Sep 2017', 'Appendix A: Schedule of Assessments', 'The schedule of required assessments is presented in this appendix. Assessments for safety and', 'patient reported outcomes are to occur corresponding with study which are fixed from Week 1 Day 1', '(W1D1) defined as the date of the first dose of study treatment. In the absence of toxicity, all', 'scheduled safety visits should occur within + 2 days of the nominal time, unless otherwise indicated.', 'Unscheduled safety assessments are to be performed weekly (or more frequently as clinically', 'indicated). Other unscheduled visits or assessments are permitted whenever necessary.', 'Page 48 of 60']['Protocol Identifying Number: PS-001', 'Protocol Version: 1.0', 'Protocol Date: 10 Sep 2017', 'Appendix A: Schedule of Assessments', 'Pre-treatment period', 'Treatment period', 'Postdiscontinuation period', 'Assessment', 'Screening (> 7 days)', 'W1D1', 'W2D1', 'W3D1', 'W7D1', 'W13D1', 'W19D1', 'W25D1', 'After beginning', 'End-of-', 'Follow-up', '5', 'of W25', 'treatment visit', 'Informed consent', 'X', 'Inclusion/exclusion criteria', 'X', 'Medical history', 'X', 'X', 'X', 'X', 'X', 'X', 'X', 'X', 'X', 'Physical examination', 'X', 'X', 'X', 'X', 'X3', 'X', 'Vital signs', 'X', 'X', 'X', 'x\u00b3', 'X', 'Performance status', 'X', 'X', 'x\u00b3', 'X', 'ECG', 'X', 'x\u00b3', 'X', '24-hour Holter ECG monitoring', 'X', 'X', 'Echocardiography', 'X', 'Cardiology consultation', 'X', 'X', '3', 'Hematology', 'X', 'Biochemistry', 'X', 'X', 'X', 'X', 'Coagulation', 'X', 'Urine analysis', 'X', '\u00df-HCG, HIV tests', 'X', 'CT/MRI', '1,2', 'Bone scan', '1,2', 'X', 'Tumour tissue samples6', 'X', 'Serum biomarkers', 'X', 'EORTO QLQ-C30, FKSI-15, PSS', 'X', 'X', 'X', 'X', 'X', 'questionnaires', 'Sunitinib and propranolol', 'Since the first day of sunitinib/propranolol administration up to the end-of-treatment visit', 'administration record', 'Blood pressure and pulse', 'Since the first day of sunitinib/propranolol administration up to the end-of-treatment visit', 'home monitoring (twice daily)', 'Adverse events', 'Since the first day of sunitinib/propranolol administration up to the end-of-treatment visit', 'Dispense/return of study', 'X', 'X', 'X', 'X', 'X', 'X', 'X', 'X', 'X', 'drugs', 'Further cancer treatment', 'Every 8 weeks (+7', 'and survival status', 'days) until the end', 'of study or death', '1 < 28 days, 2 if clinically indicated, every 6 weeks, every 12 weeks, 5 prior to first dose of sunitinib/propranolol, 6 whenever available', '3', '4', 'Page 49 of 60']['Protocol Identifying Number: PS-001', 'Protocol Version: 1.0', 'Protocol Date: 10 Sep 2017', 'Appendix B: Karnofsky Performance Status (KPS) Scale', '100 - Normal; no complaints; no evidence of disease.', '90 - Able to carry on normal activity; minor signs or symptoms of disease.', '80 - Normal activity with effort; some signs or symptoms of disease.', '70 - Cares for self; unable to carry on normal activity or to do active work.', '60 - Requires occasional assistance, but is able to care for most of their personal needs.', '50 - Requires considerable assistance and frequent medical care.', '40 - Disabled; requires special care and assistance.', '30 - Severely disabled; hospital admission is indicated although death not imminent.', '20 - Very sick; hospital admission necessary; active supportive treatment necessary.', '10 - Moribund; fatal processes progressing rapidly.', '0 - Dead', 'Page 50 of 60']\n\n###\n\n", "completion": "END"}